{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:35Z","timestamp":1787019635881,"version":"build-2736575974"},"reference-count":59,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,8]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Hemolytic disease of the fetus and newborn (HDFN) due to Rhesus D (RhD) antigen mismatch between the mother and fetus has been a significant cause of neonatal jaundice, recurrent miscarriage, and stillbirth throughout history. Polyclonal anti-RhD immunoglobulin G (RhD-pIgG), derived from the plasma of RhD-negative donors immunized with RhD-positive red blood cells (RBCs), has reduced the incidence of HDFN, but this approach is currently restricted to developed countries. Monoclonal antibodies (mAbs) offer a promising alternative to address this pressing need, but prior attempts to develop effective anti-RhD mAbs have failed, in some cases, due to differences in fucosylation patterns between mAbs produced in cell lines and RhD-pIgG. Chinese hamster ovary (CHO) cell lines, commonly used for pharmaceutical protein production, induce high levels of fucosylation, reducing the antibody-dependent cellular cytotoxicity (ADCC) activity crucial for clearing RhD-positive RBCs. In contrast, RhD-pIgG has lower fucosylation levels, which enhances ADCC activity. Regulating the glycan levels of mAbs during production requires specialized cell lines and culture conditions. In this study, we took an alternative approach through antibody engineering. The Fragment crystallizable (Fc) regions of 2 existing anti-RhD mAbs (Brad3 and Fog1) were subjected to mutagenesis to introduce ADCC-enhancing mutations and then expressed in CHO cells under standard conditions. We demonstrate that targeted Fc mutagenesis significantly enhanced ADCC compared with the wild-type mAbs, while preserving RhD binding and efficient production in CHO cells. Furthermore, these Fc variants achieved comparable efficacy with RhD-pIgG, suggesting a new strategy for producing anti-RhD mAbs with improved functionality, without the need for glycoengineering.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015082","type":"journal-article","created":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T15:00:43Z","timestamp":1734706843000},"page":"1522-1533","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Fc mutagenesis enhances the functionality of anti-RhD monoclonal antibodies"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3043-1322","authenticated-orcid":false,"given":"Behnaz","family":"Heydarchi","sequence":"first","affiliation":[{"name":"1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4881-4617","authenticated-orcid":false,"given":"Damian B.","family":"D'Silva","sequence":"additional","affiliation":[{"name":"1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5901-8753","authenticated-orcid":false,"given":"Huon","family":"Wong","sequence":"additional","affiliation":[{"name":"1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-9733","authenticated-orcid":false,"given":"Ethan D.","family":"Goddard-Borger","sequence":"additional","affiliation":[{"name":"2Department of Medical Biology, The University of Melbourne, Parkville, Australia"},{"name":"3Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7050-6822","authenticated-orcid":false,"given":"Ian P.","family":"Wicks","sequence":"additional","affiliation":[{"name":"1Inflammation Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"6720","key":"2025040814521888900_bib1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1136\/bmj.300.6720.313","article-title":"ABC of transfusion. Haemolytic disease of the newborn and its prevention","volume":"300","author":"Tovey","year":"1990","journal-title":"BMJ"},{"issue":"5","key":"2025040814521888900_bib2","doi-asserted-by":"crossref","first-page":"102946","DOI":"10.1016\/j.transci.2020.102946","article-title":"Immunohematologic aspects of alloimmunization and alloantibody detection: a focus on pregnancy and hemolytic disease of the fetus and newborn","volume":"59","author":"Gupta","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"2025040814521888900_bib3","doi-asserted-by":"crossref","first-page":"120","DOI":"10.11604\/pamj.2019.32.120.17757","article-title":"Hyporegenerative anemia and other complications of rhesus hemolytic disease: to treat or not to treat is the question","volume":"32","author":"Alaqeel","year":"2019","journal-title":"Pan Afr Med J"},{"issue":"19","key":"2025040814521888900_bib4","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1056\/NEJM196711092771908","article-title":"Suppression of the primary Rh immune response with passive Rh IgG immunoglobulin","volume":"277","author":"Freda","year":"1967","journal-title":"N\u00a0Engl J Med"},{"issue":"5570","key":"2025040814521888900_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1136\/bmj.4.5570.7","article-title":"Prevention of Rh-haemolytic disease","volume":"4","author":"Clarke","year":"1967","journal-title":"Br Med J"},{"issue":"24","key":"2025040814521888900_bib6","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1056\/NEJM199812103392410","article-title":"RhD hemolytic disease of the newborn","volume":"339","author":"Bowman","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"2025040814521888900_bib7","doi-asserted-by":"crossref","first-page":"227.e1","DOI":"10.1016\/j.ajog.2019.05.019","article-title":"The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action","volume":"221","author":"Visser","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"2025040814521888900_bib8","first-page":"1374","article-title":"Is an expression system for producing therapeutic antibodies with immunosuppressive properties found at last? Comment to letter by Dr. Quagliaroli","volume":"78","author":"Olovnikova","year":"2013","journal-title":"Biochemistry"},{"issue":"7","key":"2025040814521888900_bib9","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S2352-4642(18)30071-3","article-title":"Rhesus disease: a global prevention strategy","volume":"2","author":"Zipursky","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"suppl 1","key":"2025040814521888900_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/pr.2013.208","article-title":"Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels","volume":"74","author":"Bhutani","year":"2013","journal-title":"Pediatr Res"},{"issue":"1","key":"2025040814521888900_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.beha.2005.01.002","article-title":"Plasma protein therapies: current and future perspectives","volume":"19","author":"Farrugia","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"issue":"1","key":"2025040814521888900_bib12","first-page":"50","article-title":"Variant Creutzfeldt-Jakob disease: an update","volume":"50","author":"Ironside","year":"2012","journal-title":"Folia Neuropathol"},{"issue":"9","key":"2025040814521888900_bib13","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1111\/j.1537-2995.2006.00924_1.x","article-title":"On the immunologic basis of Rh immune globulin (anti-D) prophylaxis","volume":"46","author":"Kumpel","year":"2006","journal-title":"Transfusion"},{"issue":"1","key":"2025040814521888900_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/asheducation-2009.1.185","article-title":"Mechanisms of anti-D action in the prevention of hemolytic disease of the fetus and newborn","volume":"2009","author":"Brinc","year":"2009","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2025040814521888900_bib15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1423-0410.2007.00945.x","article-title":"Efficacy of RhD monoclonal antibodies in clinical trials as replacement therapy for prophylactic anti-D immunoglobulin: more questions than answers","volume":"93","author":"Kumpel","year":"2007","journal-title":"Vox Sang"},{"issue":"1","key":"2025040814521888900_bib16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF02433872","article-title":"Fast clearance of the rhesus-positive erythrocytes by monoclonal anti-rhesus antibodies--an insufficient condition for effective prophylaxis of rhesus-sensitization [in Russian]","volume":"129","author":"Olovnikova","year":"2000","journal-title":"Biull Eksp Biol Med"},{"issue":"11","key":"2025040814521888900_bib17","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1182\/blood-2003-11-3929","article-title":"A\u00a0single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes","volume":"103","author":"Miescher","year":"2004","journal-title":"Blood"},{"issue":"6","key":"2025040814521888900_bib18","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjh.12965","article-title":"Low anti-RhD IgG-Fc-fucosylation in pregnancy: a new variable predicting severity in haemolytic disease of the fetus and newborn","volume":"166","author":"Kapur","year":"2014","journal-title":"Br J Haematol"},{"issue":"18","key":"2025040814521888900_bib19","doi-asserted-by":"crossref","first-page":"e0079621","DOI":"10.1128\/JVI.00796-21","article-title":"Enhanced ability of plant-derived PGT121 glycovariants to eliminate HIV-1-infected cells","volume":"95","author":"Anand","year":"2021","journal-title":"J\u00a0Virol"},{"key":"2025040814521888900_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1146\/annurev.immunol.25.022106.141702","article-title":"The impact of glycosylation on the biological function and structure of human immunoglobulins","volume":"25","author":"Arnold","year":"2007","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"2025040814521888900_bib21","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J\u00a0Biol Chem"},{"issue":"16","key":"2025040814521888900_bib22","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"2025040814521888900_bib23","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1073\/pnas.0508123103","article-title":"Engineered antibody Fc variants with enhanced effector function","volume":"103","author":"Lazar","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2025040814521888900_bib24","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1158\/1535-7163.MCT-08-0201","article-title":"Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells","volume":"7","author":"Richards","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"13","key":"2025040814521888900_bib25","doi-asserted-by":"crossref","first-page":"e0021921","DOI":"10.1128\/JVI.00219-21","article-title":"Enhancement of antibody-dependent cellular cytotoxicity and phagocytosis in anti-HIV-1 human-bovine chimeric broadly neutralizing antibodies","volume":"95","author":"Edwards","year":"2021","journal-title":"J\u00a0Virol"},{"key":"2025040814521888900_bib26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.carres.2018.05.008","article-title":"Synthesis and use of 6,6,6-trifluoro-L-fucose to block core-fucosylation in hybridoma cell lines","volume":"465","author":"McKenzie","year":"2018","journal-title":"Carbohydr Res"},{"issue":"10","key":"2025040814521888900_bib27","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1021\/acschembio.6b00460","article-title":"Facile modulation of antibody fucosylation with small molecule fucostatin inhibitors and cocrystal structure with GDP-mannose 4,6-dehydratase","volume":"11","author":"Allen","year":"2016","journal-title":"ACS Chem Biol"},{"issue":"32","key":"2025040814521888900_bib28","doi-asserted-by":"crossref","first-page":"10178","DOI":"10.1002\/anie.201805165","article-title":"Recognition of complex core-fucosylated N-glycans by a mini lectin","volume":"57","author":"Cabanettes","year":"2018","journal-title":"Angew Chem Int Ed Engl"},{"issue":"41","key":"2025040814521888900_bib29","doi-asserted-by":"crossref","first-page":"33973","DOI":"10.1074\/jbc.M111.327692","article-title":"A\u00a0novel core fucose-specific lectin from the mushroom Pholiota squarrosa","volume":"287","author":"Kobayashi","year":"2012","journal-title":"J\u00a0Biol Chem"},{"issue":"12","key":"2025040814521888900_bib30","doi-asserted-by":"crossref","first-page":"e0209201","DOI":"10.1371\/journal.pone.0209201","article-title":"Red blood cell phenotype fidelity following glycerol cryopreservation optimized for research purposes","volume":"13","author":"Rogers","year":"2018","journal-title":"PLoS One"},{"issue":"1","key":"2025040814521888900_bib31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S1471-4906(00)01801-9","article-title":"Mechanism of anti-D-mediated immune suppression--a paradox awaiting resolution?","volume":"22","author":"Kumpel","year":"2001","journal-title":"Trends Immunol"},{"issue":"2","key":"2025040814521888900_bib32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.1957.tb05779.x","article-title":"Removal of incompatible red cells by the spleen","volume":"3","author":"Jones","year":"1957","journal-title":"Br J Haematol"},{"issue":"5","key":"2025040814521888900_bib33","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0167-5699(93)90166-I","article-title":"Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications","volume":"14","author":"van de Winkel","year":"1993","journal-title":"Immunol Today"},{"issue":"2","key":"2025040814521888900_bib34","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1365-2141.1991.tb07981.x","article-title":"Correlation of serological, quantitative and cell-mediated functional assays of maternal alloantibodies with the severity of haemolytic disease of the newborn","volume":"77","author":"Hadley","year":"1991","journal-title":"Br J Haematol"},{"issue":"4","key":"2025040814521888900_bib35","first-page":"247","article-title":"Serological and immunological characteristics of maternal anti-Rh(D) antibodies in predicting the severity of haemolytic disease of the newborn","volume":"56","author":"Zupanska","year":"1989","journal-title":"Vox Sang"},{"issue":"1-2","key":"2025040814521888900_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.tracli.2006.03.013","article-title":"Monoclonal anti-D antibodies to prevent alloimmunization: lessons from clinical trials","volume":"13","author":"Beliard","year":"2006","journal-title":"Transfus Clin Biol"},{"issue":"1","key":"2025040814521888900_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10517-006-0093-4","article-title":"Lymphocyte antibody-dependent cytotoxicity test for evaluation of clinical role of monoclonal anti-D-antibodies for prevention of rhesus sensitization","volume":"141","author":"Olovnikova","year":"2006","journal-title":"Bull Exp Biol Med"},{"issue":"5","key":"2025040814521888900_bib38","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood.V86.5.1701.bloodjournal8651701","article-title":"Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers","volume":"86","author":"Kumpel","year":"1995","journal-title":"Blood"},{"issue":"1","key":"2025040814521888900_bib39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S1246-7820(01)00209-9","article-title":"In\u00a0vivo studies of monoclonal anti-D and the mechanism of immune suppression","volume":"9","author":"Kumpel","year":"2002","journal-title":"Transfus Clin Biol"},{"issue":"7","key":"2025040814521888900_bib40","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood-2005-03-0989","article-title":"Intravascular survival of red cells coated with a mutated human anti-D antibody engineered to lack destructive activity","volume":"107","author":"Armour","year":"2006","journal-title":"Blood"},{"issue":"2-3","key":"2025040814521888900_bib41","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.clim.2005.10.008","article-title":"Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions","volume":"118","author":"Siberil","year":"2006","journal-title":"Clin Immunol"},{"issue":"1","key":"2025040814521888900_bib42","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41598-019-57393-9","article-title":"Anti-D monoclonal antibodies from 23 human and rodent cell lines display diverse IgG Fc-glycosylation profiles that determine their clinical efficacy","volume":"10","author":"Kumpel","year":"2020","journal-title":"Sci Rep"},{"issue":"1","key":"2025040814521888900_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2141.2008.06985.x","article-title":"A\u00a0human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies","volume":"141","author":"Beliard","year":"2008","journal-title":"Br J Haematol"},{"key":"2025040814521888900_bib44","unstructured":"Pharmacokinetics and safety of roledumab, in RhD-negative pregnant women carrying an RhD-positive foetus. ClinicalTrials.gov identifier: NCT02287896. Updated 13 July 2020. Accessed 5 January 2025. https:\/\/clinicaltrials.gov\/study\/NCT02287896."},{"issue":"4","key":"2025040814521888900_bib45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1042\/BA20090363","article-title":"Engineering mammalian cells in bioprocessing - current achievements and future perspectives","volume":"55","author":"Lim","year":"2010","journal-title":"Biotechnol Appl Biochem"},{"issue":"8","key":"2025040814521888900_bib46","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nbt.1943","article-title":"First CHO genome","volume":"29","author":"Wurm","year":"2011","journal-title":"Nat Biotechnol"},{"issue":"3","key":"2025040814521888900_bib47","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/trf.12880","article-title":"Prophylactic anti-D preparations display variable decreases in Fc-fucosylation of anti-D","volume":"55","author":"Kapur","year":"2015","journal-title":"Transfusion"},{"issue":"5","key":"2025040814521888900_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s13224-019-01234-2","article-title":"A\u00a0multicenter, randomized, open-label trial comparing the efficacy and safety of monoclonal anti-Rh (D) immunoglobulin with polyclonal anti-Rh (D) immunoglobulin for the prevention of maternal Rh-isoimmunization","volume":"69","author":"Chauhan","year":"2019","journal-title":"J\u00a0Obstet Gynaecol India"},{"key":"2025040814521888900_bib49","first-page":"1341","article-title":"Efficacy and safety of monoclonal anti-D immunoglobulin in comparison with polyclonal anti-D immunoglobulin in prevention of rho isoimmunization","volume":"50","author":"Chauhan","year":"2002","journal-title":"J\u00a0Assoc Physicians India"},{"issue":"3","key":"2025040814521888900_bib50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.5468\/ogs.2020.63.3.315","article-title":"Recombinant anti-D for prevention of maternal-foetal Rh(D) alloimmunization: a randomized multi-centre clinical trial","volume":"63","author":"Mayekar","year":"2020","journal-title":"Obstet Gynecol Sci"},{"issue":"4","key":"2025040814521888900_bib51","doi-asserted-by":"crossref","first-page":"474","DOI":"10.18231\/j.ijogr.2023.090","article-title":"Post-marketing safety evaluation of recombinant anti-rho (D) immunoglobulin forthe prevention of maternal rh-isoimmunization: a prospective, multi-centre, phase IV study","volume":"10","author":"Shah","year":"2023","journal-title":"Indian J Obstet Gynecol Res"},{"issue":"10429","key":"2025040814521888900_bib52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(23)01888-3","article-title":"Monoclonal RhD prophylaxis: high time to evaluate efficacy","volume":"403","author":"Verweij","year":"2024","journal-title":"Lancet"},{"key":"2025040814521888900_bib53","volume-title":"The Continuous Textbook of Women's Medicine Series - Obstetrics Module","author":"Contreras","year":"2023"},{"issue":"24","key":"2025040814521888900_bib54","doi-asserted-by":"crossref","first-page":"7275","DOI":"10.1158\/1078-0432.CCR-19-2030","article-title":"FDA approval summary: mogamulizumab-kpkc for mycosis Fungoides and Sezary syndrome","volume":"25","author":"Kasamon","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"24","key":"2025040814521888900_bib55","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg","year":"2024","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2025040814521888900_bib56","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S1474-4422(24)00077-2","article-title":"Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial","volume":"23","author":"Cree","year":"2024","journal-title":"Lancet Neurol"},{"issue":"16","key":"2025040814521888900_bib57","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-020-01405-w","article-title":"Tafasitamab: first approval","volume":"80","author":"Hoy","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"2025040814521888900_bib58","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10637-020-01056-4","article-title":"A\u00a0phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"39","author":"Danilov","year":"2021","journal-title":"Invest New Drugs"},{"issue":"6","key":"2025040814521888900_bib59","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.ccell.2018.05.005","article-title":"Selective Fc\u03b3R\u00a0co-engagement on APCs modulates the activity of therapeutic antibodies targeting T cell antigens","volume":"33","author":"Waight","year":"2018","journal-title":"Cancer Cell"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1522\/2362715\/blooda_adv-2024-015082-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/7\/1522\/2362715\/blooda_adv-2024-015082-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T11:21:38Z","timestamp":1744111298000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/7\/1522\/534794\/Fc-mutagenesis-enhances-the-functionality-of-anti"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,4,8]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015082","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]}}}